Note: Descriptions are shown in the official language in which they were submitted.
WO 9~t10699 ~ ~3 ~ PCT/US90/01320
~ .
:
:'
MO~RC~LAR C~ONING OF GENO~IC A~D cDN~ 8EQ~ENCE8
~CQp~ çzL~q~ r~s~ QIo9V~R~8
This application is a continuation-in-part of U,S. Serial
No. 321,957, filed March 10, 1989, the contents of which are
hereby incorporated by reference into the present
disclosure.
Backaround cf the Invention
Poliovirus i9 a small, iscosahedral ~NA-containing
picornavirus best known a~ the etiologic agent of paralytic
poliomyelitis. Infection begins when virus is ingested and
replicates in the gut, leading to a viremia. In a small
number of infected individuals, virus invades the central
nervous syst_m from the blood. Lytic viral -eplication with
motor neurons in the brain-and spinal cord results in
destruction of thesQ cells and the characteristic flaccid
paralysis~of poliomyelitis tBodian D., Science L~:105-108
1955)]~
Althoùgh during its viremic stage many tissues are exposed
to pollovlrus, replication is li~ited to the oropharyngeal
and intestinal mucosa, the PeyQr's patche~ of the ileum, and
~ motor neurons within the central nervous ~ystem. Several~
1 experimental results support the suggestion ~hat the
restricted tissuQ tropism of poliovirus is a result of
limited expression of specific viral attachment sites, or
receptors. In~b1ndinq studie~ u~inq tissue homogenate, the
poliovirus receptor is detected only in tissues that are
sites of pol`iovirus replication [Holland, J.J. Virology
1~:3~2-326 ~1961~. Furthermore, l~cX of susceptibility to
: . ,
. .
WO90/1Q699 2 ~ , PCT/US90/01320 ~
''~'',l~,'~i.
-2~ ~ -
poliovirus infection, both in primate and non-primate cell
types, can be circumvented by introducing viral RNA into the
S cells by transfection, indicating that resistance to
infection is due to a block in binding, entry, or uncoating
of poliovirions [Holland, J.J., McLaren, J.C., and Syverton,
J.T., J. Exp. Med. ~lQ:65-80 (1959)]. Finally, the results
of gene transfer experiments indicated the mouse L cells
transformed with hu~an DNA expre6s poliovirus receptors at
the cell surface and beco~e susceptible to infection `~
[Mendelsohn, C., Johnson, B., Leonetti, ~.A., Nobis, P.,
Wimmer, E. and Racaniello, V.R., Proc. Natl. Acad. Sci. USA :;
83:7845-7849 (1986)]. ~;
Work in other viral systems strongly implicates cellular
receptors in tissue tropism and pathogenesis. For example,
the human T cell glycoprotein CD4 is the receptor for HIV~
[Maddon, P.J., Dalgeleish, A.G., McDougal, J.S., Clapham,
P.R., Weiss, R.A. and Axel, R. Cell 47:333-348 tl986)]. ;;
Expression~of the CD4 on T helper cells is though to be
responsible for the selective infection and destruction of
the~e cells observed in individuals infect with HIV-I Human
CD4-negative cells, which are resistant to infection by HIV-
I, c~n be rendered susceptible to infection by transfection
with cDNA clones encoding the CD4 clones encoding the CD4 -~
receptor.
,~
Biochemical studies indicated that the poliovirus receptor
is an integral membrane protein ~Xrah, D.L. and Crowell,
R.L., Virology LL~:148-156 (1982)]. However, it has not
been possible to purify the receptor protein from membrane
preparations using assays that require binding of virus or
antibody, probably due to the liability of the respective
binding sites. Several monoclonal antibodies have been
~ ' .
W090/10699 ? ~ PCT/US90tO1320
" ;~
-3-
isolated which inhibit the binding of poliovirus to cultured
cells [Minor, P.D., Pipkin, P.A., Hockley, D., Schild, G.C.
and Almond, JoW~ Virus Res. ~:203-212 (1984); Nobis, P.,
Zibirre, R., Meyer, G., Kuhne, J., Warnecke, G. and Kock,
G.J. Gen. Virol. 6:2563-2569 (1985); Shepley, M.P. Sherry,
B. and Weiner, H.L. Proc. Natl. Acad. Scij USA 85:7743-7747
(1988)]. Monoclonal antibody D171 competes with the 3
poliovirus serotypes for a common high affinity binding site
on permissive cells and does not bind to cells that are
resistant to poliovirus infection [Nobis et al., (1985)].
HeLa cells contain approximately 100,000 D171 binding sites
(P. Nobis, personal communication) and 3000 poliovirus
binding sites tLonberg-Holm, X. and Philipson, L. Receptors
and Recognition. (Chapman and Hall, Londonj (1981)],
suggesting that virus binding is multivalent. ~ second type
of monoclonal antibody partially blocks infection with
poliovirus type 2 and to a lesser extent with poliovirus
type 1, but has little effect on type 3 binding ~Shepley et
al., (1988)]. This antibody recognizes a 100 kd protein in
the membrane of poliovirus-susc~ptible cell lines and human
spinal cord, and specifically stains neurons at the
neuromuscular junction.
~ ~
Th- subject invention discloses isolated genomic and cDNA
clones encoding poliovirus receptors from HeLa cells.
Transformation of resistant mouse cells with either of two
cDNA clones leads to expression of the receptor on the cell
surface and susceptibility to poliovirus infection.
Northern hybridization analysi~ indicates that a 3.3 kb
receptor transcript is present in many human tissues,
including kidney, which does not contain poliovirus binding
activity and which is not a site of poliovirus replication.
Thus, at least in the kidney, expression of poliovirus
. ' .';; .
W~90/10699 ~ PCT/US90/01320 ~ ~ ~
, . .
, .
.,. ~
receptor RNA is not sufficient to permit viral infection. .~.
The poliovirus receptor cDNA clones encode putative .
polypeptides of 43,000 and 45,000 daltons that contain
identical extracellular and tran~membrane domains, but
differ at the cytoplasmic tails. Protein homology -
comparisons revealed that the poliovirus receptor is a new : ~.
member of the immunoglobulin superfamily [For a review of
the immunoglobulin superfamily see: Williams, A.F, and
Barclay A.N. Ann. Rev. Immunol, 6:381-405 (1~88)]. The :; :
extracellular portio~ of the receptor may be fqlded into a :;
structure composed of 3 domains ~tabilized by intrachain
disulfide bonds. .:
;.
.
,
,;
"
-;
~ ~ 25 :
,:,
.:
~. ~
; ~
~ ~;
:
.:
.'''"; ;
w090/to699 2 ~J !~ ??;1,~ PCTtuSso/01320
" ,?'
--5--
8ummarr of the Invention
The subject invention provides an isolated nucleic acid
molecule which comprises nucleic acid encoding a polypeptide
which has the biological activity of a receptor for
picornavirus.
In addition, the subject invention provides a purified
polypeptide which has the biological activity of a receptor
for picornavirus.
The subject ~nvention also provides a method for inducing
the production of a polypeptide which includes the use of
expression vectors in a host vector system. Therapeutic
compositions comprising purified polypeptides which have the
biological activity of a receptor for picornavirus are also
provided for as are methods of treating and preventing human
poliovirus infection.
Further, the subject invention provides a method of
producing a transgenic animal expr~ssing human picornavirus.
Th~ comprises introducing DNA encodlng the picornavirus
into a fertilized egg recovered from an animal of the female
aex; transferring the resulting egg to the oviduct of a
pseudopregnant animal under conditions such that the female
I animal becomes pregnant with the egg. The animal is then ;~`
treated under conditions such that the female gives birth to
a litter; then selecting from the litter animals which
express and have stably incorporated DNA encoding human
picornavirus receptor. ``
'`: '''~
Additionally, the subject invention provides a method of ~ ;
35 testing the efficacy of a picornavirus vaccine which ~
. '~ ~ .. '
WO 90/10699 ~ ~ L~ PCT/US90/01320 ~
' '
6 ~:~
comprises administering the vaccine to a transqenic animal
described above and determining whether the resulting
5 transgenic animal is protected from infection by human ~
picornavirus. :
Lastly, the subject invention provides a method of testing ;
the virulence of a picornavirus vaccine to a transgenic : :
10 animal described above and determining the physiological :
effect of the vaccine on the animal. -:
., ::
~:
. .
/.
~
: .
,'"``,.
''"'
~.'.'~'.
~5 . , ;~ ~
.:: ' .
': '
WO90/10699 ~ ~ ~ 3 ~ ~ ~ PCT/US90/01320
rief De~crlption of the Fi~ur~
Figure 1. Analysis of receptor DNA in transformants
and in recombinant bacteriophages.
.
A) Southern blot hybridization analysis of
secondary L cell transformants
expressing the poliovirus receptor.
Ten micrograms of genomic DNAs were
digested with restriction ndonuclease
Bam HI, fractioned in 0.8% agarose
gels, transferred to nitrocellulose and
hybryidized with ~ZP-labeled RNA SP6
transcript~ from the human Alu clone
blur-8 [Jelinek et al., (1980)].
Secondary transformant cell lines CM-
1.1, CM-l.9, CM-1.17, CM-1.24 and CM-
1.27 were derived from the primary
transformant CM-l. The positions of
the markers were determined by the co-
.
electrophoresi~ of lam da DNA digested
: with Hind III. The sizes of the ~:
markers are given in kilobase pairs.
,~
B) Restriction ~ap of receptor genomic :
I clones ~PVR-2, ~XPVR-3, and ~PVR-4. :~
Solid lines indicate human sequences .
and stippled lines indicate mouse .. :~
sequences. The locations of Bam HI ;~.
restriction sites are shown. The 10 kb `~ .
and 6 kb fragments in ~PVR-2 correspond ..
to the 10 kb and 6 kb Alu-containing
BamH I ! fragments shared among .
.~.'.'.:.-
,"'. ~
,":','
. ' . ',:":
WO90~10fi99 ~Ç~ 3 ~J ~ PCT/US90/01320 ~
....... ..
-8-
.~ ,:, ..
polioviru~ receptor expressing
secondary transformants (see Figure
lA). Tha cloning site and arms of the ~-
replacement v~ctor ~2001 are not shown.
The order of the BamX I fragments in
~PVR-2 was determined by gel
electrophoresis of partial digestion
products annealed to 32P-labeled
oligonucleotide probes complimentary to
the left and right cohesive ends of
lambda DNA (Collaborative Research,
Inc.)
Figure 2. Northern Hybridization analysis.
,
A) Total cell RNA prepared from poliovirus
resistant Ltk cells and poliovirus `
susceptible cell lines including HeLa
cells, secondary L cell transformant
CM-l.9 and hum~n neuroblastoma SY5Y.
The DNA probe is the 1 kb BamH I
genomic fragoent i~olated from ~PVR-2
(Figure 1~).
. ' '
B) ~otal cell RNA prepared from
transformant~ exprossing poliovirus
I receptor cDNA clone~ pSVL-H20A and
PSVL-H20B. Also shown is total HeLa
cell RNA and RNA from Ltk cells
transformed with herring sperm DNA. ~ -
The DNA probe u~ed is the 0.97 kb EcoR -
I cDNA fragment.
..: ,,,
WO90/10699 ~ PCT/US90/01320
;.
C) Oligo d(T)-selected RNA from HeLa
cells, secondary transformant CM-1.9
. and Ltk cells. The DNA probe used is
the 0.97 kb EcoR I cDNA fragment.
Positions of 28S and 18S RNA markers
are shown in all panels.
10 Figure 3. Restriction maps of poliovirus receptor cDNA
clones. The positions of EcoR I, Xho I, Sma
I and Bgl II sites are shown for four cDNA
clones isolated from HeLa cell cDNA
libraries. Sizes of cDNA clones are: HeLa
: 15 1.7, 1,666 bp~; HeLa 1.5, 1,446 bp; H20A,
2,930 ~p plus a 0.45 kb 3'-EcoR I ~ragment
whose nucleotide seguence was not
:~ determined; H208, 2,957 bp. Clones H20B and
He~a 1.7 contain identical sequences at the
respective 3' ends which are designated by
open bars. Clone H20A contains unique 3'
end sequences to the right of the Xho I
site, drawn as a crosshatched box. Clones
; H20A and: H20B are identical from the 5 !
EcoRI site to ths Xho I site: however the 5'
: EcoR I fragment of H20A contains a deletion
of 37 nucleotides 20 bp from the 5-end. The
I first 5'-500 hp of HeLa 1.5 cDNAj which is
designated by a dotted bar, does not share
sequence homology with the other cDNA
clones; the sequence dissimilarity extends
slightly past the EcoR I site. The sizes of
the predicted proteins encoded by the
poliovirus receptor cDNAs are given in
daltons. DNA fragments used as
-
:
.'. ~
wo90/10699 ~V ~ PCT/~S90/01320 ~ ~
"~",,.
--10~
~ .;
hybridization probes in the studies are ;~
identified. ;
Figure 4. Nucleotide sequence, and predicted acid
sequence of receptor cDNAS H20A dn H20B.
5'- and 3'-noncoding sequences are not
shown. Nucleotides are numbered at the
right margin, beginning with the first in ~-~
frame ATG. A~ino acid~ are numbered above
the sequence. The signal sequence (amino ~
acld 1-20) and trans~embrane domain (amino ~,
acid 433-367) are boxed. Potential sites
for N-linked glyco6ylation are underlined.
Below are the diverged carboxy-terminal
sequences of H20A and H20B, beginning at
nucleotide 1153. -
'~ '':.;
20 Figure 5. Amino acid homology of poliovirus receptor ;
domain 1 with lg 3uperfamily members.
Identical amino acids are boxed, and ~;
conserved cysteines and tryptophan residues
are shaded. IgG lambda is the Ig lambda
chain V-II region, human Ni~-58 [Takayasu et
al.~, (1981)]. OX-2 is rat membrane
glycoprotein precursor OX-2 ~McCaughan et
I al., (1987)]. Ig kappa is mouse L6 Ig kappa
chain V region [Pech et al., (1981)].
~omologies were detected by searching the
NBRF protein databa~e with the FASTP program
~Dayhoff et al., ~1983)~ which was run with
a bias and break penalty of 6. 120 random
runs were per~ormed.
-~
- ' . ' " .
'. ,.
:; ' .
: . .. . . . ., , ~, . . , .. . .. .. , . . . . . . ~, . . - .
WO 92/02542 PCT/NL91/00139
-11-
Figure 6. Structure of poliovirus receptor
polyperptide. The domain structure of the
poliovirus receptor is based on the deduced
amino acid sequence. The 3 cysteine pairs
are shown as well as the number of amino
acids between each cysteine pair and between
the loops. Tge transmembrane domain is
designated by a stippled bar. The lengths
of the diverged COOH-terminal cytoplasmic
domains of H2OA and H2OB are given in amino
acid residues.
Figure 7. Poliovirus receptor transcripts in human
tissues and cell lines. Total RNAs from
human tissues and cell lines were analyzed
by Northern hybridization; the DNA probed
employed is the 0.4 kb Sma 1-Eco RI fragment
of H2OB (Figure 3). Human tissue samples
were obtained post-operatively or post
mortem and showed no evidence of degradation
as judged by the rations and abundance of
28S and 18S ribosomal RNAs. The B-
lymphocyte RNA was isolated from the J558
plasmacytoma line, and the T cekk RNA from
the Jurkat T cell line. Macrophages were
purified from human blood as described
[Horowitz and Silverstein, (1980)].
Positions of 28S and 18S RNA markers are
shown.
Figure 8. Restriction map of DNA inserts from cosmid
clones PRG-1 and PRG-3 containing the PVR
gene. Sites for restriction endonuclease
woso~to699 ~3 '~ PCT/US90/01320
12
BamHI ~B) are indicated. Sequences
homologous to the protein coding region of
PVR cDNA clone~ N20A and H20B (Mendelsohn et
al. 1989) are ~hown, as determined by
Southern blot hybridization analysis of the
cosmid DNAs.
10 Figure 9. Poliovirus binding assay of transgenic and
nontransgenic mouse tissue homogenates.
Homogenates of different mouse tissues were
mixed with poliovirus type Mahoney,
incubated 2 hr at room temperature, and
infectious virus was determined by plaque
assay on HeLa cell monolayers. Percent
binding was calculated as 100-(virus titer
after incubation with homogenate/virus titer
after incubation with PBS X 100).
, .
Figure 10. Infection of mice with poliovirus type 1
~ahoney. Eight transgenic Fl mice of the
PRG-1-17 line and ei~ht nontrans~enic mice
~were inoculated intracerebrally with l X 105
~ ~ pfu of type Mahoney poliovirus. Beginning
the day of inoculation and each day
thereafter, one mice was sacrificed, the
I brain and spinal cord was removed and
homogenized in PES, and the virus content of
the tissues was d~ter~ined by plaque assay
on ~eLa cells. Mice were also scored for
paralytic disease before sacrifice. On day
3 and 5 two transgenic ~ice were paralyzed;
these were both sacrificed and the titer of
vi ~ s in brain and ~pinal cord separately
~ .
'~
WO 90/1069~ 3 PCl`/US9~/01320
~ ". .. i .
':
-13~
''.` ::
determined; tho graph shows ~he average of
the value~ for th~ two mice. ~Qp_Pane}, ~:~
total mic~ paralyz~d v~r~u~ time: ~iddl~
E~çl, titer o~ v~ru~ per mg of brain:
80ttI~L P~n~l, t~ter of viru3 per mg of
spina} cord. curYe~ for transgenic and
:nontransgenic ~ice are shown.
1 o `~
,'~
: .. " ' ~. .
: :. ..:
~: ; 1 5 ` ~ .
: ` :-';, ,:
~ .
:.:
~ ! ~ ' ` `
1 ` ;` ~.
'' ~' `,
.
. ` .
~ ~ : ' ; ~: .','';:
.:
~-
~.:: .~:
,~. .: ,
:
'.::' ~`
-: ~ ::-.
~: ', ~'
:
. t' ~:: . :': ., .
WOgO/10699 ~ ~ L~ PCT/US90/01320 ~
:.
: ,..
-14-
~etalle~ De~cx1~tion o~ t~ 2~Y~ LQ~
. -;~
The subject invention providQ~ an isolated nucleic acid
molecule which co~prise~ a nueleic acid encoding a
polypeptide which has the biological ~ctivity of a receptor
for a picornavirus. Picornaviruses include rhinovirus,
coxsackie virus, echovirus and human poliovirus among
others. Human poliovirus, a ~all, iscosahedral RNA-
containing picornavirus is of particular interest to thisinvention. Nucleic acid is to include both RNA and DNA with
DNA and cDNA being the nucleic acid in the preferred
embodiment. The most preferred cDNA molecules being those
designated H20A and H20B which havo the nucleotide sequences
shown in figure 4. The sub;ect invention also provides a
cosmid expression vector which comprises a nucleic acid
encoding a po}ypeptide which has the biological activity of
a receptor for a picornavirus. Examples of cosmids which
include a nucleic acid molecul~ eneoding a polypeptide which
has the biological ac~ivity o~ ~ r~eeptor for picornavirus
include, but are~not li~itQd to th- eosmids de~ignated PRG-1
;and PRG-3. PRG-l and PRG-3 v~r- d~posited with the American
Typ Culture Collèction (A~CC) 12301 Parklawn Drive,
Rockvllle, Maryland, U.S.A. on March 9, l9gO and accorded
ATCC ~os. an~ , rQsp~etively. The deposits were
~ mado pursuant to the ~udapest Troaty for the International
I Recognition o~ the Deposit of Mieroorganisms for the
Purposes of Patent Procedure (Budap~st Treaty). The sub~ect
invention ~urther provides for the use o~ a genomic DNA
molecule.
A nucleic acid molecule encoding a 801uble polypeptide
capable of b$nding to a picornaviru- i8 also provid~d for,
as i~ the soluble polypeptid~ eneod-d by thi3 nuclaic acid.
,
,;
WO90/10699 ~ 3~ PCT/US90/01320
'"' ' '
-lS-
~ :'~,.
This nucleic acid molecule is especially useful when the ;
picornavirus comprises human poliovirus. The soluble ;
polypeptide encoded by this nucleic acid is also a product
of this invention.
A purified polypeptide which has the biological activity of
a receptor for a picornavirus is also disclosed by the
subject invention. This purified polypeptide may be
produced by any of the methods disclosed in the invention.
In the preferred embodiment, the purified polypeptide
comprises a purified polypeptide which has the biological
activity of a receptor for human poliovirus. ~ purified
peptide encoded for by the nucleic acid molecule as
described above is also provided. This polypeptide has the
biological activity of a receptor for a picornavirus.
Additionally, the subject invention discloses a purified
polypeptide encoded by the cDNA molecule H20A and is
characterized by a calculated molecular weight of 45,000. -
A purified polypeptide encoded by the cDNA molecule H20B is
characterized by a calculated molecular weight of 43,000.
This invention~further provides for expression vectors which
comprise a nucleic acid encoding any of the above-identified
polypeptides. These expression vectors include but are not
I limited to: l) an expression vector which comprises nucleic ~`
acid encoding a purified polyp~ptide which has the activity
of a receptor for a picornavirus; 2) an expression vector
which comprises nucleic acid encoding a purified polypeptide
which has the biological activity of a receptor for a human
poliovirus; 3) an expression vector which comprisas a , ,
nucleic acid encoding a purified polypeptide encoded by the
cDNA ~olecule H20~, characterized by a calculated molecular
.~ .
: ~,,
WOgO/10699 r ~ L ' pcT/usso/o132o
~ V ~
: :,,
. ~
: '
weight of about 45,000 daltons; 4) an expression vector
which comprises nucleic acid encoding a purified polypeptide
encoded by the cDNA molecule H20B, characterized by a
calculated molecular weight of about 43,000, 5) an
expression vector which comprises a nucleic acid encoding a
soluble polypeptide which has the biological activity of a
receptor for a picornavirus; and 6) an expression vector
which comprises a nucleic acid encoding a soluble
polypeptide which has the biological activity of a receptor
for human poliovirus. The above-identified expression
vectors, phage expression vectors, yeast expression vectors,
viral expression vectors, mammalian expression vectors or
any variant thereof are provided for in the subject
invention.
., .:
The subject invention also providee for a host vector system ;
which co~prises a uitable host and an expression vector as
described above. A host vector system comprises: 1) a
suitable bacterial cell and an plasmid or phage or
expression vector; 2) a suitable yQast cell and a yeast
exprecsion vector; 3) a suitable eucaryotic cell and a viral
expr-ssion vector: and 4) a suitable mammalian cell and a
maxualian expression vector.
The subject invention further provides a method of producing
I a polypeptide which comprise~ culturing or growing the host
vector systems previously described under conditions such
that the polypeptide is produced and recovering the
polypeptide. The method of producing an expression vector
and choosing an appropriate ho t vector system is known to
one skilled in the art. The novelty of the present methods
is in the use of previously unknown nucleic acids to effect
the production of polypeptides which bind to picornaviruses.
,
~ ,.
.. . . . ;., . . ~ . .... . ,.,. ,. , .,, , " ~ , ", . ..
WO90/10699 ~ V;~ 3 ~ ` ` PCT/US90/01320
:', ~,'.''''
-~7-
' ' '
Accordingly, a detailed description of known methods is not ~-
included in this section. However, specific material may be
5 found in the Experimental Detail Section. ;
.: . . .
The subject invention further provides a therapeutic
composition which comprises a therapeutically effective
amount of o~e of the above-identified polypeptides and a
pharmaceutically acceptabIe carrier. The polypeptides
include but are not limited to: l) a purified polypeptide
which has the biological activity of a receptor for a~
picornavirus; 2) a purified polypeptide which has the
activity of a receptor for a human poliovirus; 3) a purified
polypeptide encoded for by the cDNA molecule designated H20A
having the nuc}eotide sequence shown in figure 4
characterized by a calculated mol-cular weight of 45,000; 4)
polypeptide encoded for by the cDNA molecule designated
H20B having the nucleotide sequence shown in figure 4
characterized by a calculated ~olecular weight of 43,000; 5)
a soluble polypeptide capable of binding to a picornavirus;
and 6) a soluble polypeptide encoded by the nucleic acid
encoding a polypeptlde capable of binding human poliovirus.
Th- phar~aceutically acoeptable carrier encompasses any of
th~ ~tandard pharmaceutical carriers such as sterile
solution, tablets, coated tablet~ ~nd capsu}es. Typically
such carriers contain excipienta ~uch as starch, milk,
. ~ .j sugarj certain types of clay, gelatin, steric acid, talc,
vegetable fats or oils, gums, glycols or other known
excipients. Such carriers may also include flavor and color
additives or other ingredients. Compositions comprising `~
such carriers ~are formulated by well known conventional
methods. However, the compo~itions comprising the subject
polypept$des are unknown.
:, ,.
WO90/10699 C~ PCT/US90/01320 ~
-
.
Also provided for in the subject invention is an antibody
directed to any of polypeptides described above. These
antibodies may be produced by any the methods Xnown in the
art. Antibodies are to include IgG, IgA, IgD, IgA, IgM, and
antibody fragments such as F(ab' )2 and Fab.
A therapeutic composition which comprises an amount of an
antibody directed to the above-identified polypeptides to
which a therapeutically effective amount of a drug is bound
and a pharmaceutically acceptable carrier is also provided
for.
,
The antibodies may also be labelled with a detectable
marker. These may include but are not limited to markers
which are radioactive, radioopaque, paramagnetic or a metal.
These labelled antibodies may be u~ed for imaging areas of
the ~ody containing picornavirus receptors and may be
detected by x-ray or MRI imaging techniques known to those
skilled in the art.
The disclosed polypeptides of the subject invention may also
b labeled with a detectable marker. These labelled
polypeptide~ may then be used in much the same manner as the
l~b ll-d antibodies to bind to cells expressing the
picornavirus receptor. Again, the labels may include those
which are radioactive, radioopaque, paramagnetic or a metal.
30~ A further provision of the subject invention is a
therapeutant comprising a fragment of a human poliovirus
particle capable of binding to the purified polypeptide
which has the biological activity of receptor for human
poliovirus and a drug which iB att~ched to the poliovirus
particle. In the preferred embodiment, the drug is
:
WO90/10699 ~ v PCT/US90/01320
. ,~ ............................................................... .. .
:, . ...
-19-
'.' "''. '.
covalently attached. A therapeutically effective amount of
the therapeutant described above and a pharmaceutically
acceptable carrier is provided. Pharmaceutically acceptable
carriers are discussed hereinabove.
,, :.
The two described therapeutic compositions may be used to
increase the concentration of a drug in the vicinity of
cells having receptors for picornavirus or specifically
human poliovirus. The subject invention provides a method
of delivering a drug which compri~es administering to a
subject a therapeutic compo~ition, either compri~ing an
amount of: l) antibody directed to a polypeptide which has
the biological activity of a receptor for a picornavirus; or
2) a fragment of a human poliovirus particle capable of
binding to the polypeptide which ha~ the biological activity
of a receptor for human poliovirus. The method of
administering may be any of the standard methods including
but not limited to oral, intravenous, intraperitoneal,
intramuscular or subcutaneous. The exact form of
administration wlll vary depending on the effect desired and
the attendant circumstances. However, one skilled in the
art will readily~be able to determine which form of
adulni~tration~ is most appropriate and what dosage is
reguired.
.
~I The subject method provides a method of preventing in a ~ ~;
subject human poliovirus infection which comprises
administering to a subject a prophylactically effective
amount of one of the~polypeptides which has the biological
activity to bind~ human ~polioviru~. In the preferred
embodiment the polypeptide i a soluble polypeptide encoded
by a nucleic acid molecule encoding a soluble polypeptide
capable of binding to a picornaviru~, most preferably human
'~
: "~
, . " -, :
WO90/10699 ~ 9 ~ ~ PCT/US90/01320 ~ `
"''.,',. '`
-20-
.."~,~, ....
poliovirus.
,. .: .
The subject invention also provides a method of treating a
patient afflicted with a human poliovirus infection which
comprises administering to the patient a therapeutic
composition which comprises a therapeutically effective
amount of one of the polypeptides capable of binding to a
picornavirus.
'~
Both the method of preventing human poliovirus in~ection and
the method of treating a patient afflicted with human
poliovirus infection are particularly suited for use with
infants and their parents. In thi~ manner it may be used
after vaccination and as a supplement to existing oral
vaccinations. Also, by providing a direct method of "typing
up" human poliovirus, a therapy may be offered to patients
who are immunosuppressed in their immunity to human
poliovirus.
The subject invention provide~ a transgenic animal having
the DNA which encodes a polypeptides which has the
biological activity of a receptor for a picornavirus stably
int~grated into the chromosomal DNA of the animal. This DNA
~y lnclude but is not limited to: }) cDNA; 2) cDNA
de~ignated H20A having the nucleotide sequence shown in
I figure 4: 3) cDNA designated H20B having the nucleotide
sequence shown in figure 4; 5) cosmid DNA designated PRG-l:
6) cosmid DNA designated PRG-3); and 7) genomic DNA. In the
preferred embodiment the animal i~ a mouse.
A method of producing a transgenic animal expressing human
picornavirus receptor is al80 provided. This method
comprises: 1) introducing DNA encoding the picornavirus
WOgO/10699 ~ J, ;~ PCT/US90/01320
-2l-
' ,' .
receptor into a fertilized egg recovered from an animal of
the female sex: 2) transferring the resulting egg to the
oviduct of a pseudopregnant animal under conditions such
that the female animal becomes pregnant with the egq; 3)
treating the resulting pregnant f~male such that the female
gives birth to a litter; and 4) selecting from the Iitter
animals which express and have stably incorporated DNA
encoding human picornavirus receptor. The steps are
briefly: l) recovering eggs from the oviducts of pregnant
~emale ani~als; 2) microinjecting the DNA which preferably
contains a promoter ~equence into the male pronucleus; 3j
transferring the egqs to pseudopr~gnant female animal; and
4) removing tissue from the offspring to determine DNA
incorporation by sta~dard methods. ~he technical aspects of
this method is detailed in the Experimental Detail section
under Production of Transgenic Mice Expressing a Poliovirus
Receptor. In the preferred embodiment the picornavirus is
human poliovirus and the transgenic animal is a mouse.
A method of testing the efficiency of a picornavirus vaccine
is also provided. This method comprises administering the
vaccinQ to a transgenic animal which has the DNA encoding
for a polypeptide which binds to picornavirus, stably
int~grated into its chromosomal DNA ànd determining whether
the resulting transgenic animal i8 protected from infection
I by human picornavirus. Protection of the transgenic animal
may be determined~by various physiological tests including
but not limited to ~etermining the levels of virus in serum,
spinal fluid or organs, observing damage to organs caused by
the virus; and observing gross motor dysfunction caused by
the virus. In the preferred embodiment the picornavirus is
human poliovirus and the transgenic animaI i~ a mou~e.
~ . . .
. ..,:
'',
,,`,'''
WO90/10699 ~J ~ L~ J ~ ~ PCT/US90/01320
" '' '
: ;:
'' ' ' '
-22- ~ ;
Lastly, the subject invention provides a method of testing
the virulence of a picornavirus vaccine which comprises
administering the vaccine to a transgenic animal as above-
described and determining the physiological effect of the
vaccine on the animal. Thi~ method provides an economical
means for testing poliovirus vaccine, as well as other
picornavirus vaccines. Currently, primates must be used to
1~ test the virulence of the currently used vaccines. This is ;~
because human poliovirus will only effect animals which have
receptors for human polioviru~.
The subject invention provides a transgenic animal havinq `
DNA which encodes ~or a polypeptide which has the biological
activity of a receptor for picornavirus and particularly ,
human poliovirus. By allowing a vaccine to be tested
without using expensive and }imited primates, the subject
invention provides a clear advantage over the prior art.
The method for testing human poliovirus vaccine requires
primates to be sacrificed and neurological tissue to be
histologically examined to deter~ine the extent of damage
caused by various levels of the vaccine. In the preferred
embodi~ent~where the transgenic animal is a mouse and the
phy-iological effect determined i8 neurological damage, a
lo~ co~t readily repeatable method of testing virulence of
a human poliovirus is obtained using technologies currently
I employed in the primate system.
WO90/10699 ~ 3 P~T/~S90/01320
-23-
Experiment~l ~et~
C~ ru~ ~n~ Antl~o~
.,,, .:., ., ...~, .
HeLa S3 cell~ were grown in suspension culture or monolayer
as described [La Monica, N., Meriam, C. and Racaniello, V.R.
J. Virol. 57:515-525 (1986)3. Ltk aprt fibroblast- were
maintained in Dulbecco's ~odlfied Eagle's medium (DMEM)
containing 10% calf serum, lOO ~g of penicillin per ml, lOO
~g streptomycin per ml, 20 ~g bromodeoxyuridine per ml, and
~g of d;iaminopurine per ml. Ltk aprt cells were
subcultured in the same medium without bromodeoxyuridine and
diaminopurine 48 hr prior to DNA transformation. Primary
and secondary poliovirus-sensitive transformants were grown
in DMEM medium containing 10% fetal bovine serum, lOO Mm
hypoxanthine/0.4mM aminopterin/16 Mm thymidine (HAT).
~- Poliovirus strains used were type 1 Mahoney, type 2 Lansing
and type 3 Leon. The mouse monoclonal antibody D171
directed against the human poliovirus receptor was a
generous gift of~P. Nobis ENobis et al., (1985)].
D~a Sr-n-for~ation~
. .
` Ltk aprt cells (7.5 X 105) that had been cultured without
drug~ for 48 hr were seeded in lO-cm plastic cell culture
I plates 12 hr before use. Each plate was treated with 1 ml
of a DNA-calcium phosphate coprecipitate consisting of 25 ~g
of high molecular weight DNA and 1 ~g of a plasmid
containing the herpesvirus ~hymidine Xinase gene prepared as
described ~Graham, F. and van der Eb, J. Virol S2:456-457
(1973); Wigler, M., Pellicer, A., Silverstein, S., Axel. R.
Cell 1~:725-731 (1978)]. After 16 hr of incubation at 37-C
the medium was replaced and incubation was continued for an
: , .
-- . ~-
~ ~ '
~v~v~
WO90/10699 PCT/US90/01320
-24~
additional 24 hr prior to addition of HAT medium. After 2
weeks of growth in HAT medium, each plate contained lOOO~
5000 tk~ colonies.
.
Virus Infection ~
. .
To identify poliovirus-sensitive L cell transformants,
monolayers of Lt~ cells were sub~ultured 1:2, and one plate
was infected with poliovirus type l Mahoney at a
multiplicity of ~infection of O.l. After adsorption, the
plates were washed 3 times to remove unattached virus and
the medium was replaced. Aliquots of supernatants were
removed at different times after infection and virus titers
were determined by plague assay on HeLa cell monolayers [La
Monica et al., (1986)].
Rosietting an~ Plannl~g
Transformants that express poliovirus receptors were
visualized on plates of tk' transformants usin~ an n ~
rosette assay ~Littman, D., Thomas, Y., Maddon, P., Chess,
L. and Axel, R. Cell 40:237-246 (1985)]. Cell monolayers
were first treated with 1.25 ~g per ml of monoclonal
ant~receptor antibody Dl71 followed by human erythrocytes
coated with goat anti-mouse IgG antibody. Cells expressing
I the poliovirus receptor became covered with erythrocytes and
could be located, removed fro~ plates with cloning
cylinders, and grown into large cultures. Cell-cultures
were enriched for poliovirus receptor-positive cells using
a panning technique as described tMendelsohn et al.,
(1986)].
WO90/10699 ~ ~ ~v ~ ~ PCT/US90/01320
, ,
.., ,... ~ ......
-25- ~
.
RNA an~ DNA Isol~tion
Total RNA was isolated from cultured cells and tissues by
homogenization in 4M guanidine issothiocyanate followed by --
centrifugation on a cushion of CsCl [Chirgwin J., Przybyla,
A., MacDonald, R. and Rutter W. Biochem. 18:5294-5299
(1979)]. Poly A+ RNA was selected by chromatography on
prepacked oligo Dt cellulose columns ~Collaborative
Research) according to the method of the manufacturer.
Genomic DNA was prepared from cultured cells as described
~Mendelsohn et al. (1986)].
, .
15 Northorn an~ Southern Hybridi~atio~ ;~
:, :
RNA was fractioned on lS agarose formaldehyde gels
[Goldberg, D. Proc. Natl. Acad. Sci. USA 77:5794-5799
(1980)] and transferred to either Zeta-Probe (Bio-Rad) or
nitrocelluloae (Schleicher & Schuell) membranes. For
Southern hybridization, genomic DNA was digested with
restriction endonucleases (4 units/~g) under conditions
recoD ended~by~New England Biolab , and fractionated on 0.8%
ag~ro~e gels. DNA was transferred to nitrocellulose filters
accordi~g to the~method of Southern tSouthern, E.M. J. Mol.
81O1. 98:503-517 (}975)]. Conditions for hybridization of
nitrocellulose filters with DNA probes were as described
I (Schleicher and Schuell). ~he conditions for hybridization
of nitrocellulose filters with RNA probes were as described
. .
~Melton, D., Krieg, P., Rebagliati, M., Maniatis, T., Zinn,
K. and Green, M. Nucleic Acids Res. L~:7035-7056 (1984)].
A~ter hybridization, both Southern and Northern blots were
washed 3 times at room temperature then once at 65-C in 0.3M
NaCl/0.03 M sodium citrate, Ph 7.0 containing either 0.5
NaDodS04 (for nitrocellulose filters) or 1% NaDodS0~ (for
~ ~
':
. :
WO90/10699 ~f ~ ~3~ ~ ~ PCT/US90/01320
-26-
Zeta-Probe membranes). 32_p labeled DNA probes were prepared
with the oligolabelling kit (Pharmacia). Southern
hybridization with the human Alu repQat blur-8 was performed
with ~NA pr~bes synthesized in vitro with SP6 polymerase
[Melton et al., ~1984)].
~ .
Construction of G~nomic Librari-J
Genomic Libraries were constructed according to Maniatis
rManiatis, T., Fritsch, E. and Sambrook, J. Molecular
Cloning: A L2boratory Manual. Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y. (1982)], 300 ~g of high
molecular weight genomic DNA prepared from CM-1.24 L-cell
transformants was partially dige~ted with 36 units of Sau 3A
(New England ~iolabs) and fractionated on a 10-40% sucrose
gradient. Fractions containing fragments ranging in size
from 15-20 kb were pooled, ligated to ~2001 arms which were
predigested with BamH I and Hind III (Stratgene), and
packaged using Gigapack Gold extracts (Stratagene).
Libraries were plated on E. Coli P2392 and screened in
duplicate with the blur-8 RNA probe ~Jelinek, W., Toomey,
P., Leinwand, L.; Duncan, C., Biro, P., Choudary, P.,
; 25 Woissman, S., Rubin, C., Houck, C., Deininger, P. and
Sch~id, C. Proc. Natl. Acad. Sci. USA 77:1398-1402 ~1980)
using the hybridization and wash conditions described for
1 southern blots.
':, .
cDNA Libr~ri-s
: .
cDNA was synthesized fro~ Hela cell poly ~A)+ RNA purified
by two cycles of oligo d(T) cellulose chromatography. First
strands of cDNA were ~ynthesized u6ing Moloney murine
leukemia virus reverse transcript~se (Bethesda Research
- ,:
.
WO90/10699 ~ ~ 1e~ ; PCT/US90/0l320
-27-
Laboratories) according to the conditions supplied by the
manufacturer. Second strand~ of cDNA were synthesized using
the procedure of Gubler and Hoffman ~Gubler, U. and Hoffman,
B. Gene 2$:263-269 (1983)]. Following second strand
synthesis, double stranded cDNAS were treated with T4 DNA
polymerase (New England Biolabs) and ligated to EcoR I
adapters (Pharmacia). The adapter-containing cDNA was
phosphorylated using T4 polynucleotida kinase (Boehringer
Mannheim) and fractionated on Sepharose CL-6B spin columns
(5'-3', Inc.) to remove small cDNA products and unligated
EcoR I adapters. The double stranded cDNA was ligated to
EcoR I-digested ~gtlO arms ~Stratagene), and packaged using
Gigapack Gold extracts (Stratagene). An unamplified cDNA
library containing 1.2 X lo6 recombinants was plated on E.
ÇQli C600Hfl-. Duplicate filters were hybridized with DNA
probes prepared by the oligolabelling method, using
hybridization and washing conditions described for Northern
and Southern blots.
cDNA clones HeLa 1.5 and HeLa 1.7 were obtained by screening
~a HeLa ce}l cDNA library con3tructed in gtll (Stratgene,
Inc.) with the l kb BamH I genomic probe. H20A and H20B
w~r- obtained by screening the HeLa cDNA library described
abo~- with the 0.97 kb EcoR I DNA probe from HeLa 1.5.
.
I E~pr-ssion of Rec-ptor cDNA Clon--
A 1.8 Sma I-Bgl II fragment from H20A was subcloned
expression vector PSVL (Phamarcia)~at the Sma I and Bam HI
cloning sites, producing PSVL-H20A. PSVL-H20B was
constructed in a similar way using a 2.3 kb Sma I-Bgl II
fragment. ~Both constructs contain the entire coding
sequence of the polio~irus receptor. To determlne vhether
.
WO90/10699 2 0 ~ B 3 9 3 PCT/US90/01320
-28- .
these cDNAS encoded function ~ receptors, L cells were
transformed with CaPo4 preci~tates containing either PSVL-
H20A, PSVL-H20B, or herring sperm DNA, as described aboYe.
Transformed cells were assayed for susceptibility to
poliovirus infectio~ as described above. Stable Ltk~ cell
lines expressing functional poliovirus receptors were
isolated as described above.
D~ 8eguenci~g
Restriction frag~ents derived from cloned cDNA inserts
subcloned into M13 vectors [Yanisch-Peron, C., Vieira, J.
and Messing, J. Gene 33:103-119 ~1985)], and the nucleotide
sequence was determined by the dideoxy method [Sanger, F.,
Nicklen, S. and Coulson, A. Proc. Natl. Ac~d. Sci. USA
74:5463-5467 (1977)~. In some ca~es nested deletions were
constructed using the ~xo-Mung ~ystem (Stratagene) or the
Cyclone system (International Biotechnologies, Inc.).
~sol~t~o~ OS Co~d Clon~- co~t-lni~g Ths Gen- Enco~ing ~h-
C~ll R~c~ptor Fo~ 201$o~iru~ ~YR)
G-noeic DNA was prepared from HeLa cells as described
(M-nd~l~ohn et al., Cellular Receptor for Poliovirus:
Nucleotide Sequence and Expression of a New Member of the
I Immunoglobulin Superfamily, Cell, 56:855-865 (1989) and
partially digested with restriction endonuclease MboI. The
digested DNA was fractionated by electrophoresis on low
melting agarose gels. DNA~ in the size range of 36-48 kb
were excised from the gel, and the agarose was ~elted and -.
the DNA purified by phenol extraction and ethanol -:
precipitation. The DNAs were ligat~d to the cosmid vector
pWE15 (Stratagene) ehat had ~een digested with BamXI. The
,
' ':
WO 90/10699 ~ ' PCl/US90~01320
~."' . ' "~
':
--29--
ligation mixtures were packaged into bacteriophage lambda
heads (Gigapack Gold, Stratagene) and plated on E. coli
NM554 under kanamycin selection. Resulting colonies were
screened for PVR gene insert by colony hybridization
~Maniatis et al., 1982~, using DNA probes derived from PVR
cDNAs tMendelsohn et al;, 1989). A total of 1.1 X lo~
colonies were screened, and six positively hybridizing
clones were obtained. Two cosmid clones, called PRG-1 and
PRG-3, were selected for Çurther analysis. Restriction maps
of these cosmid clones are shown in Figurs 8. The DNA
insert of PRG-l is 37 kb in length and that of PRG-~ in 36
kb. Southern analysis with cloned PVR cDNA (Mendelsohn et
al., 1989) revealed that both cosmid clones contained the
PVR coding region. In addition, PRG-3 extended in the 5'-
direction more than PRG-l, while PRG-1 extended more 3' than
PRG-3.
20 C08mi~ Clones ~RG-~ ~n~ PR~ nco~- Funct~onal Y~R.
To determine whether cosmid clones PRG-l and PRG-3 encode
functional PVR, the cosmid DNAs were transformed into
cultured mouse L cells, and 48 hr later the cells were
in~ected with poliovirus as de~cribed (Mendelsohn et al.,
1989). Sa~ples of the cell culture medium were taken at O
and 24 hr after virus infection. The results (Table 2)
I indicate that both cosmid3 encode functio~al cell recep~ors
for poliovirus, as shown by the presence of virus in the
cell culture medium 24 hr post-infection. Stable L cell
transformants expressing either cosmid clone were also
established as described (~end~lsohn et al., 1989). ~oth
cosmid clones gave rise to L cell transformants expressing
PVR, as judged by susceptibility to poliovirus infection.
Poliovirus-susceptible L clone~ were obtained at a high
::,
WO9~/10699 2`~ ~ g 9 g ~ ` . PCT/US90/01320 ~
-30-
frequency (75%), indicatlng that the cosmid clones contain
PVR promoter sequences.
- TA8h~ 2
COSMID t=O
pWEl5 120 180
pSVL-~20A 80 4.3 x 104
PRG-1 90 2.4 x 104
PRG-l 80 4.3 x 104
PRG-3 30 7.1 x 103
PRG-3 llO 4.6 x 103 ~
',:
Pro~u~tion o~ ~r~nsgenio ~ic- ~pr---ing ~ Pol~o~ru~
Recoptor
A DNA fragment containing the human poliovirus receptor
gene, including promoter seguence~, may be exercised from
vector sequences using an appropriate re6triction
endonuclease,~and purified by el~ctrophoresis in low-melt ~ -
agaro~e. The bond containing the DNA fragment may be cut `;
out, the agarose melted and th~ DNA purified by phenol
eYtraction ~and~ ethanol precipitation. Ten to twenty
crogram~ of the DNA may then be centrifuged to equili~rium
in a C~C1 gradient, and the fraction containing the DNA
~I dialyzed for 2-3 days against lOmM Tris Ph 7.4, 0.2 Mm EDTA, ~ `
and stored at -20 degrees C.
`
Fertilized eggs are recoverable fro~ female mice that have
mated the previous night by dis~cting the oviducts of the
pregnant females. The eggs may be recovered and ~tored in
medium M2 ~Hogan, B., Constantini, F. and Lacy, E.
nManipulating th- Mouse Embryo: A Laboratory Manual" Cold
.', ',
WO90/10699 2 0 4 8 9 9 ~ ~ ~PCT/US90/01320
., ,,: .
,.. ..
' ''., ' '.
-31- -~
Spring Harbor Laboratory, Cold Spring Harbor, (1986)]. -
Microinjection needles are prepared from capillary tubing
(Clark Electromedical Instruments, cat number GClOOTE-15) on ;
an automatic pipet puller (David Xopf, Model 700C). The
microinjection needles may be fillad with the DNA solution, ~;
and attached to a Leitz instrument tube, connected to a
pressure injection device [Hogan et al., (1986)]. The
instru~ent tube may in turn be connected to Leitz
micromanipulator, to finely control its ~ovement. The eggs
may be placed in a depression slide containing medium ~2,
and viewed under a Ni~on Diaphot microscope eguipped with
Nomarski interference contrast optics, and the egg to be
injected is immobilized by suction on the end of flame~
polished glass holding pipet tHogan et al., (1986)]. The
microinjection needle may be inserted by pressure until the
pronucleus is seen to swell. The needle will then be
withdrawn, and the procedure repeated on the remaining eggs.
Approximately 500 eggs may be inj~cted as described above,
after which approximately 400 will remain viable. The
viable egqs may be transferred into the oviducts of
paoudopregnant female ~ice, who will carry then to term
tHogan et al., (1986)]. Approximately 15% of the ` ;~
tr~n~erred;eggs (60) will develop to term. At three weeks
of age, the terminal 1 cm of the tail of each mouse may be / ;
I removed, and DNA isolated by ~tandard procedures ~Hoqan et
al., ~1986)]. The DNAs may be analyzed by Southern blot
hybridization, using DNA probes derived from poliovirus
receptor genomic or cDNA clones, to determine which of the
mice are transgenic, and carry intact copies of the injected ~;;
gene. Each of these transgenic ~ice may be used as the
founder of a new transgenic strain. For this purpose, each
mouse is mated to a normal (non-transgenic) partner, and
:. .
W090~10699 ~ O ~ ~9 9 3 1 PCT/US90/01320
-32-
allowed to produce offspring. Tr:ansgenic offspring may be
identified by Southern blot anal:ysis of tail DNA.
Con~truct~on Or Tr~Di~gen~c Xio- k~pr-s~ing PVR PRG-1 a~d
PRa-3
Cosmids PRG-l and PRG-3 were cleaved with Notl, and the PVR :
gene fragment was isolated by gel electrophoresis in low
melt agarose. The DNA fragment was excised from the gel, ~:~
the agarose ~elted and the DNA purified by phenol extraction
and ethanol precipitation. Ten to twenty micrograms of the
DNA were centrifuged to equi}ibrium in a CsCl gradient, and :
the fraction containing the DNA was dialyzed for 2-3 days
against lOmM Tris pH 7.4, 0.2 ~M ED~A, and stored at 20C. ; .
,
Fertilized eggs were recovered from female mice that had :`:
mated the previous night, by dissecting the oviducts of the :
pregnant females. The eggs were recovered and stored in
Omedium M2 ~Hogan, B. et al., ~1986) Manipulating the Mouse
Embryo: A ;Laboratory, Manual, Cold ~Spring Harbor .
Laboratory,~Cold Spring Harbor). Microinjection needles ;~
: wer- prepared from capillary tubing (Clark Electromedical ...
25 in~truments, cat number GClOOTF-15) on an automatic pipet `;:~.
pull-r ~D~vid Xopf, Model 700C). The microinjection needles
wer- rilled with the DNA so}ution, and attached to Leitz
I instrument tube, connected to a pressure injection device
~Hogan et al., 1986). The in~trument tube was in turn :
30 connected to a Leitz micromanipulator, to finely control its .:
movement. The eggs were placed in a depression slide .;
containing medium M2, and viewed under a Nikon Diaphot .
microscope equipped with Nomarski interference contrast
optics, and the egg to be injected was im~obilize~ by ~ :
suction on the. end of flame-pol~shed glass holding pipet
.:
'~ . , ~
.
,
WOgo/10699 2 ~ ~i 8 9 9 3 ~ ~PCT/US90/01320
... .
.... ~ ,, .
;,
~ ~;
-33- ~ ~
""'.
(Hogan et al.,. 1986). The ~icroinjection needle was
inserted into the male pronucleu~ (the larger of the two
pronuclei), and DNA waC injocted by pressure until the
pronucleus was seen to swell. The needle was then
withdrawn, and the procedure was repeated on the remaining
eggs.
Approxi~ately 1000 eggs were in~ected with each DNA as
described above. The viable eggs were transferred in~o the `
oviducts of pseudopregnant female ~ice, who carried them to
term (Hogan et al., 1986). At three weeks of age, the
terminal 1 cm of the tail of each mou~e was removed, and DNA
was isolated by standard procedures (Hogan et al., 1986).
The DNAs were analyzed by Southern blot hybridization, using
DNA probes derived from poliovirus receptor cDNA clo~es, to
determine which of the mice are transgenic, and carry intact
copies of the injected g~ne.
Twenty-one of 54 mice born contained PRG-l sequences, and 13
out of 37 mice born contained PRG-3 sequences. Southern
analysis revealed that each founder mouse contained
diff-rent numbers of copies of the PVR gene, integrated in
ho~d to tail arrays.
: ''
Several~transgenic founders were mated to normal (non-
Itransgenic) partners, and allowed to produce F1 offspring.
Transgenic animals were identified by Southern blot analysis
of tail DNA. These mice were used in the studies describedbelow. The following transgenic founders were used: PRG~
17, male, which contained 10 copio~ of the PVR gene; PRG-3-
6, male, containing 4 copies of the PVR gene: PRG-3-6, male,
containing 30 copies of the PVR gone, and PRG-1-7, female,
Fontaining 30 copies of the PVR gene.
' '
.
W090/to699 2 ~ ~ 8 9;9 3. ; PCT/US90/01320 ~
Northesn Blot analysi~ o~ Tr~n~g-n~c Xou~e organ RNA ; `~
5 To determine which tran6genic mouse tissues express PVR RNA, ;~`~
a variety of organs were di6sQcted from F1 transgenic mice
and RNA was prepared by the guanidine thiocyanate technique
(Mendelsohn et al.. 1989). The RNAs were subjected to
Northern analysis, using a PVR cDNA probe. In transgenic
offspring of founders PRG-l-17, PRG-1-7, PRG-3-6 and PRG-3- ~;
9, a 3.3 kb PVR RNA was detected in all organs examined,
including brain, spinal cord, lung, liver, heart, kidney,
intestine, spleen and muscle, although expression in liver
was always ve~y low. A 3.3 kb RNA was previously detected
in all human tissues examined (Mendelsohn et al. 1989). ;
These results indicate that the PVR gene is expressed in all
organs of these transgenic mouse lines.
',: '
Polio~irus B~ndlng A8~ay- ~lth ~ou-- T~8su~ Houog-n~steJ
To determine whether functional PVR is expressed in
transgenic mouse tissuea, poliovirus bin~ing assays were
performQd on tissue homogenate~. Various organs were
~; di--octed frou PRG-}-17 F1 tran~genic mice, and 5% (w/v)
houogenatea were prepared in phosphate-buffered saline
. .
(PB6). One-tenth ml of homogenat~s was mixed with 0.0l ml
of poliovirus type l, Mahony ~train, and incubated at room
I temperatur~ for 2 hr. The mixtures were then assayed for
infectious poliovirus by plaque assay on HeLa cell
monolayers, as described ~La Monica et al., (1986) Mapping
of Sequences Required For Mouse NQurovirulence of Poliovirus
Type 2, Lansing J. Virol. 57:515-525). Binding activity
results in a decrease in the number of infectious particles
in the mixture. The type l Mahoney strain of poliovirus was
used for these studies because lt ia known that this ~train
,
.
W090/10699 2 ~ ~ 8 9 9 3 ~ PcT/us90/0l32o ~ -
-3S-
does not infect mlce! and that ~ice do not bear receptors
for this strain. ~ -
Bu-c-pt~billty of Tra~sg-nlc ~io- to ~ol~ov~ru3 Inr-ction
-
To determine whether transgenic mice expressing PVR were
susceptible to poliovirus infection, two experiments were
performed. In the first experiment, a transgenic F~
offspring of founder PRG-1-17, and 8 non-transgenic mice
were inoculated intracerebrally with 1 X 105 plaque-forming
units of type } Mahoney polioviruR. The mice were observed
daily for signs of paralysis. Each day, beginning with the
day of inoculation (day O), at lea~t one transgenic and non-
transgenic mouse was sacrificed, the brain and spinal cord
removed and homogenized in PBS, ~nd the virus content of the
tissue determined by plaque assay on HeLa cell monolayers.
The results are shown in Figure 3.
~. ...
....
. .
,
:
WO90/10699 2 0 ~ 8 9 9 3 . ` :; PCT/US90/01320 ~
,
-36-
RE 8 UI,T R
~-con~ary ~n~for~t~ ~p~ ng thi`Polloviru~
5 Rec-ptor :.;
The subject invention obtained a molecular clone of the
poliovirus receptor by employing DNA transfor~ation to
transfer susceptibility to poliovirus infection from ~eLa
cells to mouse L cells. The human receptor gene was
identified in the mouse genome by virtue of its linkage to
a human Alu repetitive aequence. The isolation of a cell
line, CM-l, derived by transformation of L cells with HeLa
cell DNA was previously described [Mendelsohn et al.,
~1986)]. CM-l cells express poliovirus receptors and are
susceptible to infection with all 3 poliovirus serotypes. ~
':' ' :'
CM-l cells contains a large amount of human DNA, as
determined by Southern hybridization analysis using a cloned
20 Alu DNA probe (Figure lA, line 1). To eliminate human DNA ~;
sequences not nQcessary for Qxpression of the poliovirus
receptor gene, Ltk cells were cotransformed with the
herpesvirus thymidine kinase gene and genomic DNA prepared
fro~ primary transformant C~-l. Five independent
poliovirua-~u~ceptible secondary transformants were isolated
as de~cribed for the CM-l cell line ~Mendelsohn et al.,
(1986)]. Southern hybridization analysis of genomic DNA
from secondary transformants, using the Alu repetitive
probe, blur-8, is shown in Figure lA. All five cell lines
contain a lO kb ~amH I restriction fragment, while all but
CM-1.17 contain both 6 kb and 2 kb BamH I frag~ents. In
addition, a 3 kb BamH I frag~ent is shared by CM-1.17 and
CM-1.27. These results indic~te that the poliovirus
receptor gene contains internal Alu repeat aequences,
35 enabling use of the blur-8 probe for the isolation, from -
'
'; ~'
~ !~ ~ 2 0 ~ 8 9 9 3 PCT/USsO/01320 ~ .
-37-
secondary transformants, of genomic clones encoding the :
poliovirus receptor. ~`
:
Isol~tion of a~no~i~ Clon~ oo~lng ~ ~olio~$rus
~ecoptor .
,:
DNA from the secondary transformant C-1.24 was used to
construct a genemic library in the replacement vector ~2001.
Approximately 400,000 bacteriophage plaques were screened ~:~
with the blur-8 probe, and 3 b~cteriophage recombinants .
containing overlapping DNA inserts were isolated (Figure .:
lB). Together the phage inserts span about 30 kb of human
: 15 genomic DNA. ~PVR-4 contains mouse sequence and there~ore
carries one of the junctions of mouse and human DNA found in
CM-l.24. ~PVR-2 contains the 6 kb and most of the 10 kb
Alu-reactive BamH I fragment which does not react with AlU,
but is present in a}l of the secondary transformants ~data ~.
not shown).~
.:
To identify exon specific probes which hybridized with RNAs ..
only in poliovirus-susceptible cells, restriction fragments
from .the genomic clones were u~ed as probes in Northern
: : 25 hybrid~zation experiments. The 1 kb BamH I restriction . :
:: ~ragment contained in ~PVR-2 and ~PVR-3 hybridized with a ::
3.3 kb RNA in HeLa cells and in SY5Y neuroblastoma cells,
I and with a 3.0 kb RNA in secondary transformant CM-l.9
(Figure 2A). The shorter size o~ the RNA in transformants
probably results from deletion of 5' and 3' noncoding exons
during integration of the receptor sequences in the mouse ~.
genome. The 1 kb BamH I fragment did not ~ybridize wlth RNA :
isolated from L calls, which do not express the poliovirus
receptor (Figure 2A).
~ :.
.
.:, . ., i~, . ~
~,
WO9~/10699 2 ~ ~ 8 9 9 3 i PCT/US90/01320 ~
.,
-38~ ;
Isolat~on of cDNa Clo~e~ ~ncodlng ~ ~ol~ovirus ~eceptor
5 To isolate cDNA clones encoding a poliovirus receptor, cDNA ~;
libraries were s~reened with the 1 kb bamH I genomic probe
described above. The result~ of Northern hybridization and
nucleotide sequence analysis indicate that four cDNA clones
isolated from ~eLa cell libraries (HeLa 1.7, HeLa 1.5, ~20A
and H20B, Figure 3) represent at least 3 different mRNA
species. All four cDNAS ~hare a central 0.85 kb fragment
.
extending from approximately the second EcoR I site through
the first Xho I 5ite. Thi~ col~on central fragment is
flanked at the 5'-end by either of two different Eco RI
fragments, and at the 3'-end by either by two Xho I-EcoR I
fragments. :~
. . .
Nuc}eotide sequence analysis of the two longest cDNA clones,
H20A and H20B, indicated the presence, in each, of an open
reading framc beginning with a methionine codon within the
first EcoR I fragmen~and ending at a termination codon at
two different locat1ons beyond the first Xho I site (Figure
3). Therefore, H20A and H20B were;te~ted for their ability
to ~direct ~expxession of the poliovirus receptor in
tran~or~ation cxpcri-ents. A 1.8 kb Sma I-Bgl II fragment
froe H20A and a 2.3 kb Sma I-~gl II fragment from H20B were
subcloned into the expres~ion vector PSV~, and Ltk cells
Iwere transformed with either con~truct or with herring sperm
DNA. Forty-eight hours after tran~formation the cells were
lnfected with poliovlrus, and the cell culture medium was
assayed for the presence of infectiou~ virus 24 hr later.
When ~ cells transformed with either PSVL-~20A or PSVL-H20B
were infected with pollovirus, large numbers of viral
progeny were produced tTable 1), confirming that the cDNA
clones encodo a poliovirus receptor. In con~rast, L cells
-- . : ,. .
',
. ~
,' '''' '~
_WO90/10699 2 0 ~ 8 9 ~ 3 PCT/US90/01320
that had been transformed with herring sperm DNA were not
susceptible to poliovirus infection. Both PSVL-H20A and
PSVL-H20A were also susceptible to poliovirus infection and ;
reacted with anti-receptor momoclonal antibody D171 `n situ .:~
rosette experiments (data not 3hown).
~ ;.,~, :'. .
"~. ,
Yields of poliovirus after infection of mouse cells .
transformed with poliovirus receptor cDNA clones.
PFU/~L
Transformina aNa 0 hours 24 hours
15 herring sperm 32 37 ~:
pSVL-H20A 9 3.4 x 106
pSVL-H20B 7 . 3.1 x 106
. . .
Ltk cells were transformed with the indicated :
DNAs and 48 hours later were infected with ,:
poliovirus type 1. PFU/ml in cell culture medium
was determined at 0 and 24 hrs post infection. -~:
: .
To confir~ that polioviru~-~usceptible transformants
cont~lning either PSVL-~20A or PSVL-H20B expressed specific
tran~cript~ of the appropriate lQngths, RNA from stable L
cell transformants was analyzed by Northern hybridization
I using the 0.97 kb EcoR I frag~ent of HeLa 1.5 (Figure 3) as
a probe. A. 2.4 kb RNA was d~tected in PSVL-H20A
transformants and a major transcript of 2.9 kb was detected
in SVL-H20B~transformants (Figur~ 2B). These are the sizes
of RNAs which result fro~ transcription of the receptor
cDNAS in PSVL. RNA prepared from L cells transformed with
herring sperm DNA did not hybridize to the 0.97 kb probe.
.:
WO90/1V699 2 ~ ~ 8 9 9 3 PCT/US9~/01320 ~ ~
~: .
-40- jt . ' . .
;,`' , '' ' ',
:'. ,~ .' '
To identify poliovirus receptor mRNA6 expressed in HeLa
cells and in secondary transformants, the 0.97 kb EcoR I
fragment from HeLa l.5 was hybridized to Northern blots
containing poly(A)+ RNA prepared from HeLa cells, secondary
transformant CM-l.g and LtX cell~ (Figure 2C). The 0.97 kb
probe hybridized to a 3.3 kb and a 5.6 kb mRNA in HeL~
cells. In the secondary transfor~ant CM-l.9, the 0.85 kb
probe hybridized to a single ~RNA species of about 3.0 kb
(the size differen e i8 vi~ible on a short exposure); no
hybridization to poly (A)+ RNA from untransformed ltk cells
was observad. ~he pre~ence of a mRNA in CM-l.9 cells which
hybridizes to HeLa receptor cDNA indicates that the cDNA
encode the receptor gene expressed in secondary
transformants.
~, .
Additional Northern hybridization analysis (data not shown)
was performed to better characterize the pattern of
transcription of polioviru receptor mRNAS. DNA probes
derived fron both shared and diverged regions of the H20A
and H20B cDNAS hybridize with th~ 3.3 kb mRNA in HeLa cells,
indicating that the 3.3 kb mRNA consists of two comigrating
~p cl-s. How~ver, the ~RNA represented ~by the H20B cDNA
25 app~ars to be le-s abundant than th~ ~RNA represented by the ;;
H2Q~ cDNA. ~The S.6 kb mRNA hybridizes to 3'-end sequences
pre-ent in H20A but not in H20B, indicating that par~ or all
Iof tho H20A soquence is contained in the Iarger transcript,
and that clone H20B is represented only in the 3.3 kb
30 transcript. '~
~''
,
~: .
W090/l0699 2 0 4 8 9 9 3 : PCT/ US90/0l320
i ~
-41~
~,',: '. ~.
Nucl-oti~o 8-quenc~ a~alyi~iJ of Poliovlruis Receptor
oDN~ Clon~s ; ~
~ :
The nucleotide and predict~d amino acid sequences of
functionally active clones H20A and H20B, beginning with the
first in-frame methionine codons are shown in Figure 4. The
S'-untranslated sequence shared between the two cDNA clones
and the diverged 3'-untranslated sequences are not shown.
The cDNA sequence beginis with 2 clo~ely packed methionine
codons, both of which obey consenisus rules for initiation
codons, with purines at the -3 and +1 positions with respect r' "
to the AUG [Kozak M.~ Cell. 44:283-292 (1986)~. Following
the first methionine is a i6tretch of 20 uncharged and
hydrophobic amino termiinal signal sequence. A transmembrane
domain, beginning at amino acid residues, typical of an
amino acid 344, is composed of 24 hydrophobic and nonpolar
amino acids followed by several basic residues. Shortly
after the transmembrane domain, the sequences of the two
cDNAS diverge, resulting in different amino acid sequences
in the cytoplasmic domain~. Clone H2OB contains a
cytoplasmic tail of 25 amlno acids in length, while clone
H2QA co~tain~ ai 50 amino acid cytoplasmic tail that is rich
in -rine and threonine residues, possibly a site of
pho phorylation. H20A and H20B contain open reading frames
of 417 and 392 amino acids, which encode polypeptides of
I approximately 45,000 and 43,000 daltons, respectively.
The sequences of H20A and H20B diverge from nucleotide 1153
with the cytoplasmic domain, through the 3' ends of the ' ' ~:!
cDNAS. The 5'EcoR I fragment of both cDNAS contains a
region of Alu homology beginning at position -29 and ending ~ ;
at -3 with respect to the A in the fir~t initiation codon.
The Alu homology begins beforo the initiating AUGs,
~.
WO9~/10699 2 0 ~ 8 9 9 3 PCT/US90/01320 ~
-~2-
,. .
indicating that this region i8 not~trànslated. The 3' non-
coding region of H20A, which is àpproximately 1.9 kb in
length, contains a ce~ond region of Alu homology beginning
at nucleotide 1663 and ending ~t nucleotide 1700 (sequence
not shown). Alu repeat elements have been found in the 3'
untranslated domains of several ~RNAS including the mouse
Class I major histocompatibility antigen [Hood, L.,
Steinmetz, M. and Malissen, B., Ann. Rev. I~munol. 1:529-568
(1983)], and the low density lipoprotein receptor [Yamamoto,
T., Davis, C.G., Brown, M., Schneider, W., Casey, M.L.,
Goldstein, J. and Russell; D., Cell ~:27-38 (1984)]. The
H20B 3'noncoding regions, which i8 1.5 kb in length,
contains a putative mRNA destabilizing sequence beginning at
nucleotide 1702 and ending at nucleotide 1752. The
destabilizer sequence consists of several tandom repeats of
the sequence A m A [Shaw, G. and Kamen, R. Cell. 46:659-667
(1986)]. The presence of this sequence may explain the
relatively low level of this RNA in HeLa cells.
.,,,.:. . .,,~,.
T~- ~olloviru- ~-ceptor i~ ~ X~b r o~ t~e
I~ounoglo~ull~ aup-rf~ily
A arch of the N~BRF protein data base revealed homology
~tY -n the poliovirus receptor polypeptides and
i~unoglobulin family members (Figure 5). The extracellular
I region of the polioviru~ receptor can be folded into a three
domain structure ~Figure 6). Each domain contains amino
acids which are highly conserved among immunoglobulin family
members. These amino acids are with B-strands which can
fold into the V1, Cl and C2 domains present in ~`-
immunoglobulin superfamily member~ tWilliams and Barclay,
(1988)]. In particular each of th8 3 poliovirus domains
contains the conaerved cy~teine pairs wh~ch usually
' .. '
WO90/10699 ~ 2 0 ~ 8 9 9 ~ j P~T/US90/01320
, ~ ;~ . . .
-~3~
~ .
stabilize the structure of the immunoglobulin do=ains.
The first domai~ in the poliovirus receptor shows the
strongest homology with human Ig lambda chains and to a ~ ~
lesser extent with rat glycoprotein OX-2 and mouse Ig kappa ~ :
chains (ALIGN scores are shown in the description of Figure
5). This domain is most likely of the V-type due to the
longer distance (73 amino acids) between cysteine residues.
The presence of C' and C~ B-strands in the v-type domain
results in the increased length between cysteine residues.
The poliovirus receptor contain~ a tyrosine at position 86
present in some C' regions of V domains/ consistent with
classification as a V-type. The homology of domains 2 and
3 with Ig family members i8 less certain, and therefore
amino acid alignments are not shown. However, these domains
contain the conserved cysteine and tryptophan residues
typical of Ig-like proteins. The highest ALIGN scores
generated from comparisons between domain 2 and Ig family
~;~ members are as follows: 2.47 with human HLA class II
histocompatibility antigen, and l.72 with human Ig gamma ~`~
constant chain. Homology comparlsons with domain 3 did not
r~lt in hLgh: ALIGN scores with Ig constant or variable
:~ 25 r-gion~. HOWQVer, domain 3 displays significant homology
wlth ~ou-e NCAM domains 3 and i (ALIGN scores 7.42 and 5.68,
r-~pQctiv~ly). Since the polioviru~ receptor does not haue
extensive homology with other protein or nucleotide ~i
sequences in the Genbank or NBRF data bases, it is probably
a new member of the immunoglobulin superfamily.
~: -
.
~pr~ on o~ Pollo~irus R-c-ptor ~a l~ ~um~ ~is~uo
An important question is whether ~xpr~ssion of poliovirus
receptor transcripts in human ti88ue5 correlates with the
Wo90/10699 2 0 ~ 8 9 9 3 PCT/US90/01320 ~ ~
known pattern of polioviru~ tis~ue tropism. Virus
replication is limited to ~ small number of sites in
primates, including the orophAryngeal ~ucosa, the Peyer's
patches in the ileum, and motor neurons in the CNS.
Replication as well as viru8 binding activity has not been
observed in most other tissues including heart, lung, and
kidney [Bodian, (1955); Sabin, A.B., Science 123:1151-1157
(1956); Holland, (1961)].;
' .
Northern blot hybridization was performed on RNA prepared
from human tissue~ to determine where poliovirus receptor
transcripts are expressed. The hybridization probe employed
was a 0.4 kb EcoR I-Sma I fragment derived from H20A (Figure
3), which contains the first 93 amino acids of the predicted
protein. A 3.3 kb transcript wa~ detected in HeLa cells and
in all the human tissues examined, including frontal cortex,
cerebellar cortex, motor cortex, kidney and ileum (Figure
7). The 3.3 kb mRNA was also detected in cells of the
immune system, including cultured B and T cells, and
macrophases isolated~from~human blood. The 0.4 kb probe did
not hybridize to RNA isolated fro~ mouse L cells.
. ~ .
In ~ddltion to the 3.3 kb transrript, the 5' probe
hybridized to a 5.6 kb RNA present only in the frontal
cortex ~F1gure 7). In a separate experiment, the same
I filter Was hybridized with the con8~rv~d 0.97 kb EcoR I DNA
probe ~Figure 3). A pattern o~ hybridization similar to
that found with the 5' probe was observed, except that the
0.4 kb Sma I-EcoR I fragment ~ay be contained in transcripts
which do not include the 0.97 kb EcoR I sequences.
Experiments, employing hybridization probes ~erived from 3'- ;
noncoding regions, suggest tlssue-specific expression o~
RNAs complementary to H20A and H208 tdata not shown). Since
: ~ ~ . ; '
~ .
.
.. ..
WO9~/10699 ~Q ~ ` PCT/US90/0132~
~u~8993 ~
,;4
_~5_ ~'''~'''
" ;~
the poliovirus receptor 3.3 kb transcript is found in the
kidney, which is not permissive for poliovirus infection and
does not bind poliovirus particle~, expression of the 3.3 kb
poliovirus receptor RNA is not ~ufficient to allow infection
of tissues by poliovirus.
DNA Blnd~ng assay - Tran~gen~c ~ic-
The results of the binding assays are shown i~ Figure 9.
These results indicate that brain, kidney, intestine and
perhaps liver of PRG-1-17 F1 transgenic mice express
poliovirus binding ites, and therefore express the PVR
transgene in a functional ~anner. Similar results were
obtained for tissue homogenates from F1 transgenic mice of
founder PRG-1-7.
:
~usc-pt~billty o~ ~r~n~gen~c ~ to ~olioviru~ Infectlon
A total of 6 out of 8 transgenic mice inoculated with
poliQVirU8 ~are paralyzed; in contrast, none of the normal
~nontransgenic) mice inoculated with virus showed any signs
of di~ase. One mouse was sacrificed on days 0 and 1 for
det-ruination of virus titers. This length of time is not
enough for de~elopment of paralysis; considering that the
I remainder of the transgenic mice subsequently became
paralyzed, it is likely that if the animals had not been
sacrificed on days 0 and 1, they would have developed
paralytic disease~. The tranqgenic ~ice ~howed classic signs
of paralytic poliomyelitis-ruff1ed fur, one or more
paralyzed limbs, and tremulous beha~ior (Jubelt et al.,
(1980) Pathogenesi~ of Human Poliovirus Infection In Mice,
I Clinical and Pathological Studlea, J. Neuropathology, Exp.
-
'
wo9o/10699 2 ~ ~ 8 9 9 3 PCT/US90/Ot320
-~6-
,
Neurol. 39:139-148). It is al80 clear that virus replicates
to high titers in the brain and ~pinal cords of transgenic
but not nontransgenic mice (Figure lO). These results
indicate that the transgenic ~ice are susceptible to
infection with a poliovirus str~in that cannot infect normal
mice, and develop a disease that appears to be
poliomyelitis.
To determine whether the tran~genic ~ouse expressing the PVR
gene could be used for testing of the live, oral
poliovaccine, the ~ollowing experi~ent was performed. Three
transgenic mice of the PRG-1-17 line were inoculated
intracerebrally with 5.4 X 105 pfu o~ type 1 Mahoney, and 2
transgenic mice were inoculated with the same amount of type
1 Sabin, the oral poliovirus vaccine strain. Four
nontransgenic ~ice were also inoculated with each virus.
About two weeks later, two of the ~ice inoculated with
Mahoney had developed paralysi~, while none of the mice
inoculated with the sabin strain had shown signs of disease.
None of the nontransgenic mice inoculated with Mahoney or
Sabin showed signs of disea~e. This experiment confirms
th~t the transg-nic ~ouse expres~ing P~ is susceptible to
25 in~-ction wlth poliovirus type 1 Mahoney. Furthermore, the
r -ult~ indicate ~that the transgenic m$ce do not develop
disease a~ter inoculation with the Sabin 1 strain, an
I attenuated virus that is part of the live, oral vaccine
administered to infants. Currently the poliovirus oral
vaccine strains are tested in Çercopitheçus monkeys; these
ani~als develop paralysi~ when inocul~ted intracerebrally or
intraspinally with neurovirulent ~trains of poliovirus, such
as type 1 Mahoney, but do not d~velop disease after
inoculation with attenuated strains ~uch as Sabin 1. The
results with the transgenic mice expFessing the PVR gene
..
.,
' .,
;;
WOgO/10699 ~ o ~ ~ 9 9 3 PCT/US9o/0132~
" , , ~ .
.
-47
suggest that this mouse model may be suitable for the
testing of poliovirus oral vaccine ~trains, and perhaps for
the development of new poliovirus vaccine strains.
~ u~io~
This invention describes the isolation of functional cDNA
clones encoding cellular receptors for poliovirus. Primary
nd secondary mouse cell transformant~ were obtained, after
:ransformatlon of L cells with HeLa cell DNA, which express
~he human polioviru~ receptor at the cell surface and are
t5 ensitive to infection with all 3 polio~irus serotypes. The
man recep-or gene was rescued from the genome of mouse
~ll transformants by probing genomic libraries with a human
r~petitive probe. Probes derived from the poliovirus
r^ceptor genomic clones were then used to isolate two
r~ceptor cDNA clones from HeLa cells, which encode
functional poIio~irus receptor is a me~ber of the
immunoglobulin family of ceil ~urface molecules.
-
S~- Yollo~ru~ ~-o~ptor ~ ao~ ~ultipl- RX~
Th- r-aults of Northern blot expQri~ents indicates that HeLa
cell- contain at least 3 transcripts which hybridize to the
I poliovirus receptor cDNAS: a 5.6 kb RNA and two RNAs that
comigrate at a~out 3.3 kb. The H20A and H20B cDNA clones
probably represent the 3.3 kb mRNAS. The origin of the 5.6
kb HeLa mRNA i9 not clear, although this RNA hybridizes to
coding and 3' noncoding probQ~ der~v~d from the H20A cDNA
but not fro~ 3'- noncoding probes from the H208 cDNA (data
not shown). These resu}~s indicate that the 5.6 kb RNA
contains H20~ sequence~ as well as ~dditional sequence~ that
' ~
2048993 ` '~`:
WO90/10699 PCT/US90/01320
. ~ '. .
: .~
. :..
-48-
~,: ......
have not been claimed.
It is likely that transcripts represented by H20A and H20
arise from a single gene. In Southern hybridization
experiments, probes derived from the 3'- end of both cDNAS
hybridize to a single restriction fragment in HeLa cells as
well as in secondary transfor~ants that express the
poliovirus receptor (data not shown). Since the
transformants contain approximately 30 kb of human DNA,
based on th~ir content of Alu-reactive sequences, it is
unlikely that two separate receptor genes give rise to ~20A
and H20B transcripts, unless the genes are very tightly
linked. Alternative splicing of 3' exons or use of
different 3 polyadenylation sites can account for the
structures of mRNAS represented by the H20A and H20B cDNA
clones, which contain different cytoplasmic tails as well as
diverged 3' noncoding sequences.
The destabilizer sequence present in the 3' end of the H20B
cDNA may function as a post transcriptional regulatory
mechanism in certain cell types. This idea is supported by
th- observation that levels of the H20L mRNA are low in HeLa
cell~ compared to th- high levels of the H20A message, which
do-s not contain the destabilizer sequence. However, other
mechanismis mi~ht also regulate levels of the two RNAs.
,.
~xpresJion o~ Poliovirus Rec-ptor mRNA ~ Poliovirus
TiJsu~ Trop1s~
,
To determine if expression of the poliovirus receptor gene
follows the same pattern reported for poliovirus binding
activity, human tissue was examined for expression of
35 poliovirus receptor transcript~. The results indicate that ~-
, ' ~;''
woso/1o699 2 0 ~ 8 9 9 3 PCTiUS9~/01320
.., ~. .
.
-~9-
expression of the binding site for poliovirus is probably
regulated by post trans~riptions events. For example,
5 Northern hybridiza~ion experiments indicate the presence of ~``
a 3.3 kb RNA in human kidney which hybridized with both
coding and 3'- noncoding probes derived from the poliovirus
receptor cDNAS. Since the kidney is not a site of
poliovirus replication and does not contain detec~able
poliovirus binding activity, it is concluded that expression
of poliovirus receptor mRNA is insufficient to encode
functional receptor activity in this tissue.
There are sevoral reasons why a receptor mRNA expressed in
kidney might not lead to detectable poliovirus binding
activity. It i8 possible that the receptor mRNA observed in
kidney is not translated into protein. Alternatively, the
mRNA expressed in kidney might encode a protein that cannot
bind poIiovirus due to differences in the amino acid
sequence. Expression of poliovirus receptor sites in
tissues might also be dependent on post translational
modification. For exampl~, the developmentally regulated
addition of negatively charged ~-2,8-linked polysialic acid
to a ~ite outside the ligand binding region is thought to
pl~y a major role in regulation of NCAM binding activity
[~d-l~an, G., Ann. Rev. Cell. Biol. ~:81-116 (1986)]. Other
types of post translational modification, such as
Iphosphorylation and sulfation of N-linked oligosaccharides,
are also thought to be involved in regulation of NCAM
activ~ty and expression [Edelman, 1986; Cunningham, B.,
Hemperly, J., Murray, B., Prediger, E., Brackenbury, R.,
Edelman, G., Saience 236:799-806 (1987)~.
Another possibility i8 that a functional poliovirus receptor
35 consists of the 45X polypeptide as30ciated with other ~
':
WO~0/10699 2 0 ~ 8 ~ ~ 3 ; PCr/US90/01320 ~ - :
: .
- ~ --s o
membrane proteins. For example, there are 2 classes of
interleukin-2 bindin~ sites present on ~ lymphocytes, a low
affinity site and a high affinity site [Robb, R., Green, w.
and Rusk, C., J. Exp. Med. 160:1126 (1984)]. Transfor~ation
experiments indicate that cloned IL-2 receptor cDNAS encode
only the low affinity binding site [Green w., Robb, R.
Svetlik, P., Rusk, c., Depper, J. and Leonard, W.J. Exp .
Med. 162:363-368 (1985)]. The association of a second
protein with the low affinity IL-2 receptor subunit is
necessary to create a high affinity IL-2 binding site
~Sharon M., Rlausner, R., CuIlen, B., Chizzonite, R. and
Leonard, w., Science ~ 859-863 (1986)]. Perhaps high- -
- 15 affinity binding of polioviru3 is mediated by a similar
mechanism.
Since poliovirus is not the natural ligand of the receptor
that we have cloned, the regulation of the binding site is
probably important for the natural function of this
receptor. If the receptor participates in cell recognition
or adhesion, as do other members of the immunoglobulin
family, it might be expected that expression of the activity
of thi~ protein would be tightly regulated, both in a
d-velopment and~tissue specific fashion.
It is known that tissues such as kidney and amnion, which do
Inot express binding sites for poliovirus, can be induced to
express receptor activity by dispersion of the tissues and
subsequent culture in vitro [Holland, ~1961)]. If
expression of the poliovirus binding site is regulated by ~-
post translationàl modification of the receptor protein, the
modification might be induced by culturing organs or tissues
in yitro. Alternatively, ancillary proteins required for
35 virus binding activity might be induced by in vitro ~
,'; ~ ."
'~
WO90/10699 2 0 ~ 8 9 9 3 -; PCT/US90/01320
. . .
-5~;
culturing.
The Poliovlrus Reo~ptor l- a ~-~b-r of the ~mu~oglobulin
~uperf ~'~ ly
Protein homology comparisons revealed regions of amino acid
conservation between the poliovirus receptor and members of
the immunoglobulin family. The poliovirus receptor is a
third known member of the i~munoglobulin family which
functions as a virus receptor. The CD4 receptor expressed
on cells of the immune system ha~ been shown to be the
receptor for HIV-l, the causative aqent of A~DS [Maddon et
al., (1986)]. ~Intercellular adhesion molecule 1 (ICAM-l),
which widely expressed in human tissues, is the major
rhinovirus receptor (Greve and McCelland, personal
communication). An interesting question is whether the
domain structure common to molecules of the immunoglobulin
family is a common feature of proteins that mediate the
entry of certain viruses in cells, or simply reflects the
fact that many cell surface molecules are Ig-like. It
shoul~ be noted that known receptors for several other
VirU~Q-, such as~influenza virus and Epstein-Barr virus, are
i~munoglobulin family members [Weis W., Brown, J.H., Cusack,
S., Paulson, J.C. Skehel, J.J. and Wiley, D.C., Nature
333:426-431 (19881; Fingeroth J.D., Weis, J.J., Tedder,
I T.F., Strominger, J.L., Biro, A.P., and Fearon, D.T. Proc. -;
Natl. Acad. Sci. USA ~l:4510-4514 tl984)].
Atomic structures for poliovirus ty~e l and rhinovirus type
14 reveal a common cleft in the virion, called the Hcanyonn,
which encircles each of the 12 vertices of the iscosahedral
capsid [Rossman~ N.G., Arnold, E., Erickson, J.W.,
Frankenberger, E.A., Griffith, J.P. Hect, H.J., Johnson,
' '~ - .
~ '
''2
W090/10699 ~n~ PCT/US90/~1320
2 ~ 48 ~
" :,
; .., :
-52~
',' .
J.E. and Xramer, D.J. Science 22~:1368-1365 (1985). This
cleft has been proposed to be the site on the virion that
attaches a cellular receptor [Ro~man~t al., tl985)]. It
has been sugge~ted that the relative inaccessibility of the
canyon to the host immune ~y~te~ allows the virus to
maintain such a binding site free from the evolutionary
pressure generated by most neutralizing antibodies.
Surrounding the canyon are pro~ontories formed by exposed
loops of amino acids~ whose sequences are relatively
variable and which contain so~e of the well characterized
antigenic sites associated with dif~erent viral serotypes
~Hogle et al., (1985)]. Mutations introduced into the walls ;
and floor of the rhinovirus canyon alter the affinity of the
virus binding, supporting the canyon as the receptor binding ;~
site [Colonno R., Condra, J., Mizutani, S., Callahan, P.,
Davies, M. and Murcko, M. Proc. Natl. Acad. Sci. USA
85:5453-6559~(1988)]. Since both poliovirus and rhinovirus
use receptors that are Ig-like, it is tempting to speculate
that the picornavirus canyon i~ particularly suited to
attach to the domain structure of Ig-like molecules.
Identification sf additional picornavirus receptors will be
roquirQd to address this question. It will also be of
interest to determine whether the CD4 binding site on gpl20
of HIV is also a canyon-like structure.
I Poliovirus is believed to enter cell~ by receptor-mediated
endocytosis, with a low pH phase required for virion ~;
uncoating ~Madshus, I.H., Olsnes, S. and Sandvig, K.J. Cell.
Biol. 98:1194-1200 (1984)]. The availability of a
functional, cloned copy of a poliovirus receptor will enable
analysis, by site-directed mutagenesis, of regions of the
receptor required not only for viru~ blnding but for entry
and uncoating. It may al~o be po-sible to solve the atomic
',,:'
, ~'
"',.. .
WO 9~)~10699 2 ~ 4 8 9 9 3 ~ Pcr/us9o/o132o
r~
structure of the receptor polypeptide as well as the virus- :
receptor co~plex. Together the results between virus and ~ :
5 its cellular receptor, knowledge of which may be crucial for ::
designing future antiviral strategie~
It will also be important to identify the natural function
of the poliovirus receptor. ~any ~embers of the Ig family :. :
10 participate in cellular recognition and adhesion, and .the .~.
functional cDNAs of the subject invention may be used to
determine whether the poliovirus receptor is capable of
mediating these~acti~ities.
.
~ ~ 15
`
,~
,: .
~ 25 ~; `
.
' :":
,
,,
:''',' ~'
~' ...;
. :
`~
,",,,,:
